A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
Completed · Phase 1
Conditions studied: Macular Degeneration
In brief
This multicenter, non-randomized, open-label, single- and multiple-ascending-dose study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6867461 in patients with wet age-related macular degeneration.
Key facts
- Study ID
- NCT01941082
- Run by
- Hoffmann-La Roche
- People needed
- 24
- Starts
- 2013-12-01
- Expected to finish
- 2015-02-01
- Last updated by the study team
- 2016-11-02
Who can join
Age: 50 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adult patients, >/= 50 years of age
- Patients with age-related macular degeneration (AMD)
- Best corrected visual acuity (BCVA) of 20/40 to 20/400 (Snellen equivalent, on ETDRA charts) inclusive
- Evidence of leakage due to choroidal neovascularization (CNV)
You may not qualify if…
- Choroidal neovascularization (CNV) in either eye due to causes other than age related macular degeneration, such as ocular histoplasmosis, trauma, or pathologic myopia
- Known hypersensitivity to ranibizumab, fluorescein, indocyanin green (ICG) or any of the ingredients of the formulation used, or any of the medications used
- Any other restriction according to the use of ranibizumab
- Active intraocular inflammation (grade trace or above) in the study eye
- Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
Where it is running
- Study site — Colorado Springs, Colorado, United States
- Study site — Baltimore, Maryland, United States
- Study site — Dallas, Texas, United States
- Study site — Houston, Texas, United States
- Study site — Charlottesville, Virginia, United States
- Study site — Belfast, United Kingdom
- Study site — Bristol, United Kingdom
- Study site — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.